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Abstract 
 
Background 
Methyl-aminolevulinate (MAL) photodynamic therapy (PDT) involves selective 
accumulation of a photosensitiser, protoporphyrin IX (PpIX), primarily in tumour tissue, 
which in combination with visible light and tissue oxygen results in reactive oxygen 
species (ROS) production and thus cellular destruction. 
 
Methods 
A non-invasive fluorescence imaging system (Dyaderm, Biocam, Germany) has been 
employed to acquire colour (morphological) and fluorescent (physiological) images 
simultaneously during dermatological PDT.  This system had been previously utilised for 
fluorescence diagnosis, however here changes in PpIX concentration within the skin 
lesions and normal tissue were followed after MAL application.  Measurements were 
also recorded from a synthetic PpIX standard.   
 
Results 
Results indicated that imaging distance, imaging angle, position of the region of interest 
and light conditions all altered the PpIX levels acquired from the synthetic PpIX 
standard.  The imaging system was therefore adapted and a standard operating 
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procedure developed allowing reproducible images of dermatological lesions to be 
acquired.  Different concentrations of synthetic PpIX were analysed with the system and 
a linear relationship was observed between the PpIX concentration and the mean 
greyscale value calculated for the images acquired up to 10 µM.  
 
Conclusions 
The Dyaderm imaging system can now be used reproducibly with confidence to semi-
quantify PpIX (within the range of 0 to 10 µM) within dermatological lesions using the 
standard operating procedure derived from this work.  
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Introduction 
 
Photodynamic therapy (PDT) selectively ablates abnormal tissue and it is now a 
widespread treatment modality for a variety of different cancers (1, 2).  PDT involves the 
accumulation of a photosensitiser, which in combination with light and tissue oxygen 
result in the production of singlet oxygen and other reactive oxygen species (ROS) 
causing cellular destruction (3) via apoptotic and necrotic cell death pathways (4).  
 
PDT has been used successfully to treat numerous dermatological lesions including 
actinic keratosis (AK), Bowen’s disease (BD) and superficial basal cell carcinomas 
(sBCC) (5).  These lesions often present treatment complications for standard treatment 
modalities due to their size, location or multiplicity.  PDT often negates these issues and 
is also associated with excellent cosmesis (6).  It is therefore an important treatment 
methodology for certain subsets of lesions within these conditions. 
 
The treatment of dermatological lesions with PDT involves the topical application of 
prodrug, either 5-aminolaevulinic acid (ALA) (7) or its methyl ester (MAL) (8).  The 
exogenously applied ALA or MAL is absorbed through the skin following topical 
application and becomes a substrate in the haem biosynthetic pathway, bypassing the 
normal negative feedback inhibition of this pathway and resulting in accumulation of 
haem and haem precursors (9).  The intermediate compound preceding haem is the 
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endogenous photosensitiser protoporphyrin IX (PpIX) and therefore photosensitisation 
of the cells occurs (9).  The preferential accumulation of PpIX in tumour tissue is 
primarily influenced by the disrupted stratum corneum and differences in 
porphobilinogen deaminase and ferrochelatase expression (10).  The methyl ester of 
ALA (MAL; commercially Metvix®, Galderma, U.K.) is currently licensed in the U.K. for 
the treatment of sBCCs, AKs, and BDs, and the current consensus indicates 
considerable treatment success in these indications (5, 11).  
 
The photosensitiser PpIX is activated by several wavelengths of light, with most intense 
absorbance occurring at 410 nm.  However for clinical PDT a longer wavelength of light 
(635 nm) is utilised to activate the photosensitiser, as despite lower absorbance, the 
depth of light penetration in tissue increases at this longer wavelength, increasing the 
efficacy of the treatment (12).  
 
PpIX exhibits characteristic fluorescent properties and therefore fluorescence can be 
used as a diagnostic tool.  PpIX exhibits red fluorescence (peak wavelengths at 635 nm 
and 700 nm) when excited by blue light (wavelength 410 nm) and therefore cells 
accumulating PpIX can be identified (13, 14).  Fluorescence diagnosis in ALA-PDT can 
aid the identification of pre-cancerous lesions and ensure the whole lesion is properly 
removed during tumour excision (15, 16).  The fluorescent properties of PpIX could also 
be potentially exploited to follow the changes in PpIX concentration within the skin 
during PDT.  Currently clinical changes in photosensitiser concentration during ALA or 
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MAL induced PDT are poorly understood.  It is known that increasing photosensitiser 
levels in the treatment area results in better clinical outcomes when ALA is employed as 
the prodrug (9).  Therefore semi-quantitative information about accumulation and 
dissipation of PpIX during ALA-PDT would provide an important insight into the 
treatment process.  In particular this information may allow a more individual treatment 
regime to be developed depending on PpIX accumulation within the lesion.  However, 
the ability to follow the level of PpIX within lesions throughout PDT has to date been 
limited by the poor reproducibility of results and numerous factors influencing 
fluorescence detection (17, 18).  Many parameters including tissue autofluorescence, 
tissue detector geometry and the absorbing and scattering properties of tissue 
contribute to quantification errors (19).  
 
Previous investigations into the accumulation of PpIX due to the exogenous application 
of ALA or MAL have utilised invasive techniques to determine the presence and 
concentration of the photosensitiser within the tissues.  Chemical extraction from tissues 
followed by high performance liquid chromatography analysis (HPLC) indicated that 
PpIX was the predominant porphyrin present in tumour tissue treated with ALA (20, 21).  
As a result the concentration of PpIX accumulating within lesional skin could be 
determined by chemical extraction, however this would require invasive surgery and the 
fluctuations throughout clinical PDT could not be followed, this technique of PpIX 
quantification therefore has limited practical application in real-time monitoring in the 
clinical environment.  
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This investigation validates a commercially available non-invasive fluorescence imaging 
system (Dyaderm, Biocam, Germany).  Whilst it is possible to conduct fluorescence 
imaging with a number of different setups (22) including non-commercial ‘home made’ 
systems (which are commonly used in pre-clinical and clinical PDT monitoring) (23-25, 
8) a commercially available piece of equipment (Dyaderm) was selected here as it could 
be purchased internationally in a standardised format.  This is important as the majority 
of dermatology clinics conducting PDT treatments do not have the facilities or expertise 
to develop their own fluorescence imaging equipment and may simply want to be able 
to buy a piece of equipment for this dual purpose of fluorescence diagnosis and 
fluorescence monitoring or indeed use an existing piece of fluorescence diagnosis 
equipment for this extended use (fluorescence monitoring).  The fluorescence imaging 
system selected was employed to acquire colour and fluorescent images 
simultaneously and non-invasively to follow changes in PpIX levels in lesional and non-
lesional skin during various time points of clinical PDT, following validation with an in 
vitro fluorescence standard.  The system was validated and adapted to ensure that the 
changes witnessed in PpIX levels during PDT were accurate and not due to 
environmental or user induced artefacts. The PpIX concentration range for which this 
system was accurate was also considered.  
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Materials and Methods 
 
Imaging Apparatus 
PpIX fluorescence was recorded using a non-invasive imaging system (Dyaderm, 
Biocam, Germany).  The system consists of a flash light (Xenon light source with a 
custom bandpass filter (370–440 nm)) and a 12-bit Sony charge coupled device (CCD) 
camera combined in one adjustable arm coupled to a Pentium IV computer equipped 
with custom-made image capturing software (Dyaderm Pro v2, Biocam, Germany).  The 
flash light emits seven light pulses per second to the skin, and the light that returns to 
the skin is collected by the CCD camera (exposure time 100 µs) equipped with a special 
Schott GG 455 longpass filter which filters out the excitation light.  The excited PpIX 
emits light in the form of fluorescence in the red spectrum; the red pixels of the CCD 
camera (spectral sensitivity of which at 630 nm is between 85% and 90%) are used to 
generate a fluorescence image.  In this way, a normal coloured image and a 
fluorescence image can be simultaneously collected and processed by the system in 
real time.  
 
Other fluorophores within the skin will also be activated by the blue light, including 
lipopigments and flavins.  These other fluorophores as well as endogenous background 
levels of PpIX are accounted for in the autofluorescence image.   
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In Vitro Setup 
In order to ensure an accurate assessment of PpIX concentration to enable its 
quantification during PDT it was essential to analyse various parameters to alleviate any 
environmental or user induced alterations in the PpIX level.  To analyse the individual 
parameters (detailed below) the camera was initially clamped perpendicularly to a 630 
nm fluorescent standard (Figure 1A) (Biocam, Germany).  Various parameters were 
then altered and the mean greyscale values of a synthetic PpIX standard analysed.  
This PpIX standard was supplied by the manufacturer of the imaging system (Biocam, 
Germany) and simply comprised of presynthesised PpIX which had been hermetically 
sealed to render it inert.  
 
Analysis of Fluorescence Images 
Images from the fluorescent standard and the patients were recorded in bitmap format, 
to ensure that no information was lost when condensing the data.  These were then 
exported into NIH ImageJ software (http://rsb.info.nih.gov/ij/).  This enabled the raw data 
to be analysed without the modifications applied by the supplied Biocam software.  The 
mean pixel intensity of the standard was then calculated for the circular region 
illustrated in Figure 1.  
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Parameters Analysed 
 
Warm up: The system was analysed to determine whether a warm-up phase prior to 
image acquisition was required.  Over a two hour period the standard was imaged every 
five minutes.  This experiment was repeated on two separate days. 
 
Light conditions: The light conditions within the room were altered and the standard was 
imaged multiple times for the different light conditions.  The light conditions within the 
room were altered by changing the overhead lights and/or opening and closing the door 
and/or curtains.  
 
Placement: The position of the standard under the camera lens was altered (e.g. top of 
field versus the centre of field etc.).  Multiple images were then acquired from each 
location. 
 
Imaging Distance: The camera is supplied fitted with a spacer that is three and half 
centimetres long.  The affect of acquiring images without the spacer was analysed in 
terms of fluorescence intensity and quality of the image.  The camera was moved in one 
centimetre increments away from the standard (0 – 6 cm).  For each position three 
images were acquired and analysed in ImageJ. 
 
Activation Time of Camera: The camera was left active acquiring images continuously 
for various periods of time.  Two data sets were acquired in 5 second increments from 
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60 seconds down to zero and a second set in reverse (in 5 seconds increments from 
zero up to 60 seconds).   
 
Angle: The angle between the camera and the standard was altered up to twenty 
degrees either side of the normal (perpendicular) angle and multiple images of the 
standard were acquired at each angle.   
Statistical significance was determined at the P < 0.05 or P < 0.01 employing the 
analysis of variance (ANOVA) for multiple groups or the Student’s t-test where only two 
variables were being considered.  
 
Reproducibility  
The reproducibility of the system was analysed by acquiring multiple images of the 
fluorescence standard attached to white card.  The standard was imaged twenty-eight 
times and the acquired images were subsequently analysed in ImageJ.   In addition the 
system was adapted based on the analysis of the above parameters and the images 
produced by the adapted system were also analysed in a similar manner.  As this 
system was going to be employed to image patients’ dermatological lesions, the 
reproducibility of the standard system and the adapted system was also analysed by 
imaging a normal human leg.  The multiple images acquired were analysed in ImageJ in 
two ways: i) the mean greyscale values were calculated and ii) the spread of the data 
was analysed.  In addition images were compared to the initial image.  If the system 
was completely reproducible then the subsequent images should have been identical to 
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the initial image.  The subsequent images were subtracted from the initial image 
acquired in imageJ and the resulting image’s mean greyscale value was analysed.  
 
PpIX Concentration Range 
Different concentrations of synthetic PpIX ranging from 1 nM to 10 mM were set up in 
96 well plates.  The fluorescence produced in each well was first studied using a 
previously validated Synergy HT plate reader (excitation 400/30 nm, emission 630/40 
nm) in our laboratory.  The solutions were then analysed using the non-invasive 
fluorescence imaging system.  A sample (10 µl) of each well was pipetted onto parafilm 
and placed under the camera of the Dyaderm system (which was clamped at right 
angles to the surface) on top of black card. Images were acquired centrally under the 
camera from 3.5 cm away (i.e. the spacer distance) and the lights were on within the 
room.  Initial studies indicated narrower concentration ranges (0 – 100 µM) should be 
considered which were subsequently conducted and analysed in a similar manner.  
 
Clinical Data Capture 
With research ethics committee approval patients attending the photodynamic therapy 
clinic in the Dermatology Department, Royal Cornwall Hospital, were consented for 
imaging with the Dyaderm system.  Images of the lesion to be treated were acquired 
prior to the application of Metvix, after the three hour application period and following 
the light irradiation period.   The images were then analysed using ImageJ software to 
follow the changes in PpIX fluorescence within the lesion.  Images of autofluorescence 
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were also analysed in a similar manner to determine if significant changes in 
autofluorescence were observed during MAL-PDT.  
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Results 
 
Warm up 
The warm up profile analysed the first two hours of system activation.  The mean 
greyscale value of the standard was analysed for every image acquired in the two hour 
period (Figure 2).  The experiment was repeated on two separate days to also 
determine the variability of the system on different days.  The results indicated a short 
initial warm up phase on each occasion.  In the first half an hour a significant difference 
was witnessed between the ten minute time intervals (P < 0.05).  After this initial period 
no significant difference was seen for the remainder of the two hours (P < 0.86).  All 
subsequent experimentation was therefore conducted at least thirty minutes after 
turning on the machine.  Comparison of the two days indicated no significant variability 
within the system on different days (P < 0.16).  
 
Light Conditions 
The mean greyscale value for the standard was determined for different light conditions 
within our PDT clinic room.  It was observed that the mean greyscale value from the 
standard was dependent on the light conditions within the room (Figure 3A, P < 0.05).  
The role of light conditions were then analysed further with images acquired in subtly 
different light conditions (Figure 3B).  The light conditions were therefore standardised 
for the rest of the experimentation with images being acquired with the light off, door 
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closed and curtains closed.  Initial image acquisition with patients also used this format, 
however it was not trivial to align the camera to exactly the same position in the dark 
and therefore future clinical images were acquired with the lights on, door closed and 
curtains closed instead as reproducible placement was considered to be critical.    
 
Placement 
The standard was imaged at different positions under the camera lens and the mean 
greyscale value recorded from the standard in each position was calculated.  Movement 
of the standard from a central location under the camera resulted in a significant 
decrease in the mean greyscale value in all cases (Figure 4, P < 0.01).  Care was 
therefore taken in all subsequent experimentation to keep the area being investigated 
central to the camera’s imaging field.  
 
Imaging Distance 
The standard was imaged at varying distances from the camera lens and the mean 
greyscale value calculated.  Alterations in imaging distance from the recommended 3.5 
cm resulted in unfocussed images and significant differences in the mean greyscale 
values (Figure 5, P < 0.05). These data highlight the importance of using the spacer 
provided with the Dyaderm equipment when taking images.  
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Activation Time of Camera 
The fluorescence standard was imaged with altering time periods of camera activation 
and the mean greyscale value recorded. The results indicated that the time period of 
camera activation did not significantly alter the PpIX level recorded from the synthetic 
standard (Figure 6, P < 0.37).  The shortest camera activation feasible was therefore 
employed for subsequent experimentation and care was taken not to take longer than 
sixty seconds, as beyond this period had not been investigated.  
 
Imaging Angle 
Alteration of the camera angle resulted in a significant difference in the mean greyscale 
value recorded from the standard (P < 0.05).  However, when the angle was altered 
there was also a small change in the distance which was not compensated for and this 
could also be adversely affecting the results.  The change in distance from the camera 
to the standard was only minimal however and therefore adjustment of the imaging 
angle from the normal resulted in significant differences in the mean greyscale value 
recorded from the standard (Figure 7).  Great care is therefore required to ensure all 
images are taken with the camera placed perpendicular to the surface being imaged.  
Whilst the perpendicular angle did not provide the highest level of fluorescence intensity 
from the standard, subsequent experimentation was carried out at a perpendicular 
angle as it was easier to maintain.  The fluorescence intensity measured was greatest 
when recorded at an angle of -20 degrees from the perpendicular.  It is likely that this 
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occurred because at this angle significant scattering from the surface of the PpIX 
standard was being collected.     
 
Reproducibility  
Based on the previous experiments the system was adapted and analysed for 
reproducibility.  Due to the system’s dependency on angle and the inherent difficulties of 
maintaining a constant angle when imaging patients the system was adapted to 
alleviate these issues.  The modifications involved either the attachment of an angular 
ruler or the attachment of a combination square.  The various adapted versions and the 
unmodified camera were utilised to acquire multiple images of the PpIX standard (28 
images acquired with each modification) and a normal human leg (50 images acquired 
with each modification) removing and replacing the camera each time to mimic the 
conditions within the clinical setting.  The coefficient of variance (CV) was calculated for 
the data and when imaging the standard a CV of 4 % was observed for all three 
versions (Figure 8).  However, when imaging the normal human leg the version with the 
combination square provided the best reproducibility with a CV of 10 % in comparison 
with 12 % for the other two versions (Figure 9A).  Additionally the subsequent images 
acquired of the human leg were compared to the initial image taken with the ImageJ 
software, by subtracting the subsequent images from the initial image.  If the images 
were identical the mean greyscale value of the resultant image should have been zero, 
the combination square had a significantly lower mean for the resultant images 
indicating the best reproducibility (ANOVA P < 0.05, Figure 9B).  Therefore the 
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combination square was utilised for subsequent patient imaging, with the exception of 
only a few lesions, where the lesion localisation meant that the combination square 
could not be placed appropriately. 
 
PpIX Concentration Range 
The PpIX range of the non-invasive fluorescence imaging system was analysed by 
employing synthetic solutions of PpIX.  A broad concentration range (1 nM to 10 mM) 
was analysed with a fluorescence plate reader as well as the fluorescence imaging 
system (Figure 10A & B respectively).  The observed plateau was due to dimerisation of 
PpIX at high concentrations.  This needs to be considered in the clinical setting as true 
changes in the photosensitiser will not be observed if PpIX accumulates to a sufficient 
concentration to result in dimerisation.   Subsequent analysis of the 0 – 10 µM range 
indicated a linear relationship with the mean greyscale values quantified with both the 
plate reader and the Dyaderm system (Figure 10C & D respectively). Although linear 
regression indicated that the plate reader was more accurate (Figure 10C; r2 = 0.99), 
the imaging system still produced an acceptable degree of accuracy (Figure 10D; r2 = 
0.91) considering its potential to be employed non-invasively during clinical PDT. 
 
Clinical Data 
A 75 year-old male patient with actinic keratosis on his right temple (Figure 11A) was 
imaged at three different time points during the treatment (Figure 11B, C & D). The 
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images were then analysed using ImageJ software and this indicated a statistically 
significant increase in PpIX fluorescence ( P < 0.01) after three hours of Metvix 
application as well as a statistically significant decrease in fluorescence (with PpIX 
concentration returning to the initially observed level; P < 0.01) following the irradiation 
of the lesion (Figure 11E).  The pre–Metvix PpIX fluorescence level was found to not be 
significantly different to the final post irradiation PpIX fluorescence level (P < 0.70).  The 
lesion was therefore observed to undergo a statistically significant change in 
fluorescence during PDT.  A similar response has been witnessed in other actinic 
keratosis lesions where a detectable fluorescence change was witnessed during PDT 
(Figure 12A).  There was large inter-patient variation resulting in the relatively large 
standard deviations observed.   All lesions were observed to accumulate a significant 
increase (P < 0.05) in fluorescence after the three hour application of Metvix, whereas a 
significant decrease (P < 0.05) in fluorescence was observed immediately after light 
irradiation had finished.  Autofluorescence changes were also recorded (Figure 12B) 
throughout PDT and no significant change was witnessed in the patients’ 
autofluorescence (P > 0.75).  It should be noted that autofluorescence values were 
subtracted from the corresponding greyscale value of the PpIX fluorescence image 
throughout.   
20 
 
Discussion  
 
The fluorescent properties of PpIX are commonly used in dermatological fluorescence 
diagnosis (26, 27, 16, 18) allowing identification and complete excision of a lesion, pre-
treated with MAL or ALA.  However, to further understand the role of PpIX in the 
efficacy of clinical MAL–PDT the concentration changes of PpIX in lesional skin during 
the treatment need to be followed.  This will provide an insight into how different lesions 
accumulate the photosensitiser and subsequently respond to PDT.  Previous studies 
have indicated that greater accumulation of PpIX and subsequent photobleaching 
during irradiation result in greater cell kill (28, 9).  Therefore the potential ability to relate 
changes in PpIX concentration during light irradiation to final clinical outcome may 
further our understanding of PDT and thus aid clinical enhancement, by developing 
more individualised treatment routines.  
 
Previously attempts to follow changes in lesional fluorescence during PDT have only 
looked at accumulation of PpIX and numerous concerns have been raised due to lack of 
reproducibility of images and the sensitivity of the system (18).  The non-invasive 
imaging system employed in this study (Dyaderm, Biocam, Germany) has been 
validated here to ensure that the changes in fluorescence witnessed during PDT were 
due in the main to actual changes in PpIX concentration alone and not user or 
environmental induced artefacts.  
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Fluctuations were witnessed in the fluorescence level of the PpIX standard employed 
immediately after the system had been switched on.  Images of the standard acquired 
within the first half an hour significantly (P < 0.05) differed from images acquired 
thereafter (Figure 2), the system therefore needs to be switched on for a period of half 
an hour prior to the initial image acquisition to allow a sufficient warm-up period.  The 
system has also been shown to be consistent; the warm-up profile was followed on 
separate days under the same conditions and no significant fluctuations were observed.  
 
Alteration of light conditions within the room, significantly (P < 0.05) altered the mean 
greyscale value recorded from the PpIX standard (Figure 3).  In particular the switching 
on of the overhead lights within the room significantly altered the mean greyscale values 
of the images.  Additionally subtle variations of the light conditions within the room (by 
opening or closing the door and/or the curtains) also altered the mean greyscale value 
recorded from the standard, although not to a significant degree.  When taking images 
from patients during PDT the light conditions within the room therefore need to be 
maintained and our standard protocol is now that both the door and curtains are closed 
(to limit the effect of external light) and the internal lights are kept on when obtaining the 
fluorescence images (to enable the imaging system to be aligned in exactly the same 
position).  In light of our initial clinical data, the changes witnessed during the treatment 
are usually of such a sizable nature that small alterations in the external light conditions, 
although significant for the standard are likely to be clinically irrelevant and thus an 
acceptable level of error in clinical practice.  It should be noted that we also routinely 
image the PpIX standard before and after clinical data acquisition to check that the 
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measurements made by the system on each day of use are as expected and to date we 
have observed no evidence that the PpIX standard provided with the system bleaches 
over extended or repeated exposures. 
 
Variations were also witnessed in the mean greyscale value recorded from the PpIX 
standard when its position relative to the camera was altered (Figure 4).  Images 
acquired from a central location under the camera lens had significantly (P < 0.01) 
increased mean greyscale values in comparison to those imaged around the periphery 
of the lens.  Therefore care has to be taken to ensure that when lesions are imaged 
they are aligned centrally under the camera to ensure fluctuations in PpIX fluorescence 
are due to changes in the PpIX concentration alone.  This is particularly important when 
repositioning the camera to the same lesion at different points in the PDT process.  
 
These validation studies verified the use of the spacer (3.5 cm) provided with the 
imaging system.  The images of the standard acquired at alternative distances away 
from the camera lens resulted in significant differences (P < 0.05) in mean greyscale 
values (Figure 5) and unfocused images.  The spacer therefore must be in contact with 
the patient’s skin to ensure that images are acquired at the same distance to ensure 
that the images are focussed and the values obtained are reproducible.  It is 
acknowledged that in some instances the positioning of the spacer is not trivial as some 
lesions are not appropriately located for its easy application.  
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The most intense absorbance of PpIX occurs at 410 nm (12).  The imaging system 
employed here utilises light in this region and therefore the effects of prolonged camera 
activation were analysed on measurements taken from the synthetic standard (Figure 
6).  There was no significant alteration in the mean greyscale value of the standard 
during periods of sixty second activation.  However, due to the propensity of PpIX to be 
photobleached by blue light, a maximum activation limit of sixty seconds has been 
imposed when imaging patients.  Further investigations could be conducted to consider 
this factor in more detail in clinical practice.  
 
Alterations in the angle of the camera relative to the standard indicated that angular 
variations significantly (P < 0.05) altered the images acquired (Figure 7).  Angular 
changes of as little as 5º from the normal perpendicular position significantly altered the 
images.  The angle of the camera relative to a lesion therefore needs to be maintained. 
The system in our experience required slight adaptation to ensure a constant right angle 
as in our previous clinical experience we have found (data not shown) that there can be 
a large degree of human error in the placement of the camera.  The first adaptation 
involved the addition of a combination square, which maintained a normal angle.  An 
alternative adaptation involved the addition of an angular ruler, where the angle of 
placement could be altered depending on localisation.  The reproducibility of the 
adapted versions was compared to that of the unmodified camera in the acquisition of 
multiple images from the standard (Figure 8) and a normal human leg (Figure 9).  The 
initial experiments with the standard indicated little variation in the reproducibility of the 
different systems (CV 4 % for all systems), however it was concluded that imaging at a 
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constant angle would be less trivial when it came to a patient.  The findings when 
imaging a normal human leg indicated that a lower spread of data and lower CV was 
seen for the combination square and that this adaptation resulted in significantly (P < 
0.05) lower deviations of subsequent images from the initial image acquired. 
Consequently the combination square adaptation has been utilised when imaging 
patients to enhance the reproducibility of the images.  Certain lesion localisations may 
not lend themselves to the placement of the camera at a normal angle and therefore in 
our experience despite no significant improvement in reproducibility, the angular ruler 
may occasionally need to be used to ensure placement of the camera at the same 
angle relative to the lesion. 
 
The authors acknowledge that the fluorescence standard utilised here does not provide 
an environment comparable to skin tissue, where the optical properties of the tissue will 
significantly affect the attenuation of the excitation light (17, 29).  However these initial 
investigations have enabled adaptation and development of a standard operating 
procedure enabling reproducible images to subsequently be obtained from normal 
human skin (Figure 10).  
 
Analysis of synthetic solutions of PpIX indicated that the non-invasive imaging system 
quantified PpIX in a similar manner to the Synergy HT plate reader (Figure 11) albeit not 
to such a high degree of accuracy.  A linear relationship was witnessed between the 
PpIX concentration of the solution and the mean greyscale values of the images 
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recorded by the imaging system in the 0 – 10 µM range (Figure 11D).  Further analysis 
of the system indicated that the relationship between PpIX concentration and the mean 
greyscale value was not linear beyond 10 µM.  Initial clinical data recorded (Figure 12) 
has indicated that the majority of data we collect clinically when conducting 
dermatological PDT does fall primarily within mean greyscale values which are linearly 
related to the synthetic PpIX concentration, although some PpIX values prior to light 
irradiation may exceed this range slightly (mean estimates of PpIX levels from these 
data are ~0.80 M pre MAL application, ~10.00 M post MAL application and ~0.75 M 
post irradiation).  However, the quantification of data collected clinically into actual PpIX 
concentrations should only be done with careful consideration.  The standard curves 
were produced from synthetic PpIX and this does not correspond directly to images 
acquired in vivo due to the complex nature of skin tissue and the heterogeneity of PpIX 
within tissue (30, 31).  In addition the limited penetration of blue light into deeper skin 
layers may cause PpIX deep within lesions to be undetectable (32).  However, 410 nm 
light has been shown to penetrate well with greater than 70% incident light reaching 
depths of 0.1 – 0.15 mm and therefore the light should penetrate the depth of the 
epidermis where the majority of PpIX will be localised (33).  The synthetic PpIX 
solutions demonstrated that the non-invasive imaging system does detect PpIX 
fluorescence and that increasing concentrations correlate to an increase in fluorescence 
observed with the system.   
 
The clinical data collected were analysed and presented in the figures semi-
quantitatively utilising image analysis rather than converting the images to actual PpIX 
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concentrations due to the aforementioned issues.  To accurately determine the PpIX 
concentration, chemical extraction would be necessary.  This has not been undertaken 
here but a previous study has shown a positive correlation between the in vivo 
fluorescence witnessed with the Dyaderm to biochemical tissue PpIX content (32). 
  
Initial clinical data (Figures 11 & 12) verify the ability of the system to detect changes in 
PpIX fluorescence during PDT treatment.  These data indicate the large changes 
witnessed in these actinic keratosis lesions at the various points in the treatment 
considered.  The significant changes in PpIX witnessed within the clinical setting are 
crucial as they further aid the practical application of the system.  Despite the 
importance of alleviating variations in PpIX due to user or environmental induced 
artefacts, the large changes witnessed clinically ensure that subtle variations that 
cannot be alleviated by following the standard operating procedure derived here are not 
clinically relevant or detrimental in this setting.   The CV of the imaging system on a 
large area of normal human leg was calculated to be 10 % for the imaging system 
modified with the combination square.  When monitoring real-time dermatological PDT 
much greater changes were observed: large increases in fluorescence intensity 
occurred after MAL application (> 300 % increase in the example presented here) and a 
correspondingly large decrease was observed following light irradiation (75 % 
decrease).  Due to the nature of PDT, tissue autofluorescence is expected to alter 
during the treatment of the lesions (29).  The non-invasive imaging system records 
autofluorescence at 410 nm at which flavins and lipopigments will provide an 
autofluorescence signal (34).  Image analysis indicated no significant change in 
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autofluorescence (Figure 12B) and therefore the changes observed in fluorescence 
reported herein are primarily due to the accumulation/dissipation of PpIX within the 
lesions. 
 
The findings from this investigation have indicated that with subtle adaptation and 
consistent application the Dyaderm non-invasive fluorescence imaging system can be 
utilised to produce reproducible measures of PpIX levels during dermatological PDT.  
Therefore semi-quantitative measures of PpIX within lesional and non-lesional tissue 
can be reproducibly determined/followed during clinical dermatological PDT in a non-
invasive manner for the first time using this commercially available equipment.  
 
Comparison of images acquired in the future, prior to the application of ALA or MAL, 
immediately prior to irradiation and following irradiation of the lesion with light will 
provide large quantities of information for analysis and detailed study.  For instance this 
information will provide insights into whether the lesions currently licensed for treatment 
with Metvix all consistently accumulate PpIX and respond in the same manner to the 
treatment and whether other currently non-licensed dermatological conditions may also 
benefit from PDT treatment.  In addition with further investigation the results may help to 
indicate relationships between changes in PpIX concentration and the final clinical 
outcome, as previous investigations indicate that greater PpIX photobleaching 
correlates to greater cell kill (27, 35).   If quasi-continuous monitoring of PpIX 
fluorescence were to be attempted during the light period in the future however, it would 
28 
 
be necessary to temporarily switch off the light source in order for fluorescence 
images/measurements to be taken. 
   
The ability to utilise this non-invasive fluorescence imaging system reproducibly to 
follow the changes in PpIX within clinical dermatological lesions could further our 
understanding of clinical PDT.  The majority of current knowledge relating to the 
accumulation of PpIX in PDT comes from in vitro studies (36-38) rather than actual 
clinical application.  However, the system described here can now be utilised to 
determine PpIX levels/changes in a non-invasive manner whilst therapeutic clinical 
dermatological PDT is in progress and as such is a useful advancement to the field.  
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Figure Legends 
 
Figure 1: A photograph of the fluorescent standard with a circle indicating the region 
analysed in ImageJ.   
 
Figure 2: The warm up profile of the imaging system produced by taking images of the 
same fluorescence standard over a two hour period on two separate days. The solid 
circles represent data collected on day one (linear trend indicated by solid line) and the 
unfilled circles represent data collected on day two (linear trend indicated by dashed 
line). Error bars indicate the standard deviation between the five images acquired of the 
standard at each time point and have been presented unidirectionally for each data set 
for clarity. 
 
Figure 3: Mean greyscale values of the standard recorded when the light level within the 
room was altered. The dark grey bars indicate when the light was off and the light grey 
bars relate to when the light was switched on. A) Indicates the significant difference in 
mean greyscale value observed when considering the status of the overhead lights 
alone (P < 0.05) and B) indicates the alterations observed by opening and closing the 
door and/or curtains within the room. + indicates parameters chosen for future 
experimentation and ++ indicates the parameters used in the clinical acquisition of 
images. Error bars indicate the standard deviations of the twenty images acquired for 
each different light condition.  
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Figure 4: Bar chart illustrating the alteration of the recorded greyscale value of the PpIX 
standard when placed at different positions under the Dyaderm. There was a 
statistically significant difference in the mean greyscale value of the standard recorded 
(ANOVA analysis indicated difference at P < 0.01) between the central position and all 
other regions. + indicates the parameter employed for all future experimentation. Error 
bars indicate the standard deviation of the multiple images acquired in each position.  
 
Figure 5: Plot indicating the alteration in mean greyscale values of the standard as the 
camera lens was moved further away from the fluorescence standard. + indicates 
distance employed when taking subsequent PpIX measurements. Error bars indicate 
the standard deviation of the 20 images acquired at each distance.  
 
Figure 6: Plot indicating the alteration in mean greyscale value for increasing and 
decreasing periods of camera activation. The unfilled circles indicate the values taken in 
order from 60 s to 0 s whereas the solid circles indicate values taken in the reverse 
order (i.e. from 0 s to 60 s). Statistical analysis indicated there was no significant 
difference between the two groups (P > 0.05). Error bars indicate the deviation of the 
mean greyscale value when the experiment was repeated three times in each direction.  
 
Figure 7: Plot indicating that the imaging angle significantly altered the recorded 
greyscale value from the fluorescence standard. Alterations of the camera imaging 
angle by as little as 5º significantly altered the mean greyscale value of the standard 
(ANOVA P < 0.05). + indicates the angle employed when taking subsequent PpIX 
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measurements. Error bars indicate the standard deviation of the 20 images acquired for 
each angular placement.  
 
Figure 8: A) Box and whisker plot indicating the range of PpIX values obtained using the 
different setups to try to ensure a perpendicular imaging angle from a standard. The 
central line indicates the mean, the box indicates the data within the interquartile range 
and the whiskers indicate the standard deviations of the data with the dots representing 
outliers. B) Bar chart indicating the mean difference in greyscale value of subsequent 
images from the initial image acquired using the three different setups. The error bars 
indicate the standard deviation of the mean difference observed.  
 
Figure 9: A) Box and whisker plot indicating the range of PpIX values obtained using the 
different setups to try to ensure a perpendicular imaging angle from a normal human 
leg. The central line indicates the mean observed, the box indicates the data within the 
interquartile range of the data and the whiskers indicate the standard deviations of the 
data with the dots representing outliers. B) Bar chart indicating the mean difference in 
greyscale value of subsequent images from the initial image acquired using the three 
different setups. The error bars indicate the standard deviation of the mean difference 
observed. The combination square was significantly more reproducible than either of 
the other setups investigated (P < 0.001) and was therefore employed in future 
experimentation (+). 
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Figure 10: Plot of PpIX fluorescence intensity versus Log PpIX concentration recorded 
with A) the Synergy HT plate reader and B) the fluorescence imaging system. 
Additionally plot of PpIX fluorescence intensity versus PpIX concentration indicating the 
linear regression lines for the 0 – 10 µM concentration range recorded with C) the 
Synergy HT plate reader and D) the fluorescence imaging system. Error bars on all 
panels indicate the standard deviation of five samples at each concentration.  
 
Figure 11: A) White light image indicating an actinic keratosis lesion on a man’s right 
temple. Images B, C, and D indicate the change in PpIX fluorescence through the PDT 
treatment process, where B) is the initial image acquired prior to Metvix application, C) 
is the fluorescence image after Metvix had been applied for three hours and D) is the 
fluorescence image immediately after light irradiation had been completed. The images 
shown (A-D) are magnified by a factor of three. E) The bar chart highlights the changes 
in the mean greyscale value of the fluorescence images (error bars indicate the 
standard deviations in the pixel intensity in the area analysed).  * indicates a statistically 
significant difference (P < 0.05) in fluorescence after the application of Metvix for three 
hours in comparison to the initial fluorescence image and the image post irradiation.  
 
Figure 12: A) Bar chart indicating the mean greyscale values recorded from a series of 
twenty different actinic keratosis lesions at different points in the treatment.  The error 
bars indicate the standard deviations in the pixel intensity in the area analysed. Paired t-
test indicated a statistically significant difference in PpIX accumulation after MAL 
application (P < 0.01) and PpIX dissipation (P < 0.01) after light irradiation.   The large 
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standard deviations reflect large inter-patient variations.  B) Bar chart indicating mean 
greyscale values for autofluorescence recorded in the twenty patients undergoing PDT. 
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